Home » USA Broker Ratings » ABIOMED – Consenus Indicates Potential 25.3% Upside

ABIOMED – Consenus Indicates Potential 25.3% Upside

ABIOMED with ticker code (ABMD) now have 5 analysts covering the stock with the consensus suggesting a rating of ‘Buy’. The target price ranges between 240 and 149 and has a mean target at 195.8. Given that the stocks previous close was at 156.27 this would imply there is a potential upside of 25.3%. The day 50 moving average is 150.35 and the 200 day moving average is 174.88. The company has a market cap of $7,015m. You can visit the company’s website by visiting: http://www.abiomed.com

Abiomed engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter-based axial flow pump. In addition, the company engages in the development of Impella 5.5 and Impella BTR that are percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.

Join us on our new LinkedIn page

Follow us on LinkedIn